NEUROSCIENCE INSTITUTE AT STANFORD (NIS)

September 27, 2004

NIS: The Rationale• Disorders of the nervous are devastating and

increasingly common.• As a result of advances in basic research, we are

learning to decipher disease mechanisms, encouraging prospects for effective new treatments.

• But, a variety of factors combine to slow the pace of applying the benefits of research to patient care.

A NEW MODEL IS NEEDED TO ACCELERATE RESEARCH LEADING TO TREATMENTS

NIS: The VisionA new culture for neuroscience- that encourages dialogue between scientists, clinicians, patients and industry- that motivates and supports fundamental

neuroscience research- that rapidly translates discoveries into enhanced care for those with disorders of the nervous system- and that sends the message that we are rededicating our efforts to the service of patients.

OutreachEducation

Clinical Care

BasicScience Research

Translational Research

ClinicalResearchNISNIS

To Integrate-To Translate-To Educate

NIS: The Model

To Integrate

-across disciplines

-scientists and clinicians

-professionals and patients/advocates

-across academic institutions

-academia, industry, government

NIS: The Model

To Translate:A Re-Definition

The process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease;

AND

The process of taking insights and ideas developed through the study of human disease to generate new scientific insights.

Bench Bedside

Neurons

Cognition

Neuronalsystems

Genes

Development

• Clinical trials • Industry

Delivery

• Health Care

Neuroscience

Translating Research Advances

Academia Doesn’t Push: Industry Often Doesn’t Pull

Neurons

Cognition

Neuronalsystems

Genes

Development

• Clinical trials • Industry

Delivery

• Health Care

Science

Translating Research Advances in the NIS

Breaking Down Barriers to Progress

NIS: Why Now?• We understand, as never before, how the

brain is built and how it functions.

• We have powerful new tools to further elucidate brain structure and function.

• Recent advances have set the stage for significant improvements in diagnosis and treatment of nervous system disorders.

NIS: Why Here?• The Stanford neuroscience community is

recognized nationally and internationally for its contributions to basic and clinical science.

• It addresses all levels of nervous system investigation.

• Stanford neuroscientists recognize the enormous promise that its work holds for enhancing the lives of patients with neurological and mental disorders.

NIS: Why This Model? Because to accelerate progress the NIS must-

• Foster a culture that recognizes and supports the importance of fundamental and disease-relevant.

• Be able to integrate acrossall levels of analysis of brain function.

• Embrace physician-scientists, clinicians, patients and industry as vital to the effort.

NIS

Cores

Theme Groups Training

Working Groups

Outreach

NIS: The PartsExec. Cmte. Adv. Council

NIS: The Working GroupsInvolve scientists, clinicians, patients, industry

- To focus on solving basic and/or clinical neuroscience problems

- To define the “state of the field”

- To point to knowledge gaps

- To apply resources to fill those gaps

- To accelerate development of tools and concepts

- To accelerate translation to patient care

Investigators: Robert Malenka, Craig Garner, Irving Weissman, Barbara Sommer, Allan Reiss, Dick Tsien, William Mobley.

“Abnormal Synaptic Structure and Function in Down Syndrome: Elucidating Genetic, Molecular and Cellular Mechanisms Leading to Treatments to Enhance Cognition”

Working Group on Down Syndrome

Discovers genes and mechanisms

Discoverstreatments

Defines the problems

Delivers treatments

THE WORKING GROUP

Stroke - Greg Albers, Gary Steinberg, Michael Moseley,

Pak Chan, Robert Sapolsky Parkinson’s Disease- Theo Palmer, Rich Reimer, Helen Bronte-Stewart,

Jamie HendersonDevelopmental Motor Disorders-Terry Sanger, Scott Delp, Krishna ChenoyPain- Sean Mackey, Dave Yeomans

Working Groups in the Making

Alzheimer’s Disease- Tony Wyss-Coray, Mike Grecius, Bill MobleyMultiple Sclerosis/Neural Regeneration- Ben Barres, Larry SteinmanBrain Tumor- Larry Recht, Griff Harsh, Mark SchnitzerSleep-Emmanuel Mignot, Craig HellerEpilepsy- Robert Fisher, John Huguenard

Working Groups in the Making

BasicInterface

Clinical

Research

Now

Future

NIS : The Expectation